



The International Symposium on
Ocular Pharmacology & Therapeutics

13th ISOPT *Clinical*

Scientific Program



www.ISOPTClinical.com

Thursday, December 1, 2016

Morning Sessions – Hall A (Sala Loyola)

09:00-10:30	Wet AMD Chair: <u>P. Lanzetta</u> , Italy	Hall A
09:00	Squalamine Drops for Wet AMD: Update <u>P. Lanzetta</u> , Italy	
09:10	Synopsis of Comparison Studies: CATT, IVAN, MANTA, GEAFAL <u>F. Boscia</u> , Italy	
09:20	Fovista Combination Therapy for Neovascular AMD <u>J. Mones</u> , Spain	
09:30	Regeneron Combination Therapy for nvAMD <u>R. Singh</u> , USA	
09:40	Phase III Studies Comparing the Efficacy and Safety of Brolucizumab vs Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration: Testing an Alternative Treatment Regimen <u>B. D. Kuppermann</u> , USA	
09:50	New Drugs in Development for Wet AMD <u>P. Lanzetta</u> , Italy	
10:00	LUMINOUS Study <u>A. Augustin</u> , Germany	
10:10	Emerging Therapies for Retinal Degenerations <u>J. Mones</u> , Spain	
10:20	Panel Case Discussion Management of Wet AMD <u>P. Lanzetta</u> , Italy, <u>M. S. J. Katz</u> , USA, <u>J. Mones</u> , Spain, <u>B. D. Kuppermann</u> , USA	
10:30-11:00	Coffee Break	
11:00-12:40	Diabetic Macular Edema Chair: <u>P. Udaondo</u> , Spain	Hall A
11:00	Protocol T <u>R. Singh</u> , USA	
11:10	Tie2 Activation with AKB-9778 in the Treatment of Diabetic Eye Disease: Results from the TIME-2 Study <u>B. D. Kuppermann</u> , USA	
11:20	Bevordex: Corticosteroid v Anti-VEGF for Diabetic Macular Edema <u>M. S. J. Katz</u> , USA	
11:30	Steroid Implants for DME <u>P. Udaondo</u> , Spain	
11:40	Combination Therapy for Diabetic Macular Edema <u>A. Augustin</u> , Germany	
11:50	Guidelines for the Use of Laser, Anti-VEGF, or Steroids in DME <u>P. Udaondo</u> , Spain	
12:00	The Role of Inflammation in the Comparison of DME Trials <u>B. D. Kuppermann</u> , USA	
12:10	The Role of Pharmacotherapy in Altering the Course of Diabetic Retinopathy <u>F. Boscia</u> , Italy	
12:20	Drugs in the Pipeline for DME <u>R. Singh</u> , USA	
12:30	ILUVIEN: Area Under the Curve (AUC) Pharmacokinetics – The CONSTANT Analysis: AUC comparisons to Protocol I Ranibizumab, Deferred Laser and OZURDEX <u>B. D. Kuppermann</u> , USA	

Thursday, December 1, 2016

Morning Sessions – Hall B (Sala Foscolo)

08:00-09:00	Retina - Free Papers Chairs: <u>H. Klassen</u> , USA & <u>A. Ohira</u> , Japan	Hall B
08:00	Preparation and In-Vivo Evaluation of Nanoliposomes Containing Melphalan after Intravitreal Injection in Albino Rabbits <u>M. Abrishami</u> , Iran	
08:10	Synthetic 9-Cis-Beta-Carotene Inhibits Photoreceptor Degeneration in Retinal Explants of RPE65/Rd12 Mouse Model of Retinoid Cycle Defect <u>I. Sher</u> , Israel	
08:20	Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa <u>H. Klassen</u> , USA	
08:30	Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection <u>M. Abrishami</u> , Iran	
08:40	Study on the Rise of the Macular Pigment Optical Density and Thiol Antioxidant Activity by Lutein Administration <u>A. Ohira</u> , Japan	
08:50	Q&A	
09:00-10:30	Anterior Segment Imaging Chairs: <u>P. A. Asbell</u> , USA & <u>C. Baudouin</u> , France	Hall B
09:00	In Vivo Confocal Microscopy in a Shared Model of Clinical Research Practice - The Real World <u>P. Hamrah</u> , USA	
09:12	Novel Imaging Technologies of the Ocular Surface <u>V. Perez</u> , USA	
09:24	Multimodal Imaging of the Cornea <u>O. Stachs</u> , Germany	
09:36	Mechanism of Visual Disturbance in Dry Eye <u>S. Koh</u> , Japan	
09:48	New Technologies for Corneal Imaging <u>C. Baudouin</u> , France	
10:00	Ultrahigh Field MRI in Ophthalmology <u>O. Stachs</u> , Germany	
10:12	Review of All the Technologies and Diagnostics Used to Diagnosis Ocular Surface Disease the Good, the Bad, and the Ugly <u>R. Toyos</u> , USA	
10:24	Q&A	
10:30-11:00	Coffee Break	
11:00-12:30	Contact Lens & Eye Pain Chairs: <u>P. A. Asbell</u> , USA & <u>P. Aragona</u> , Italy	Hall B
11:00	What Is New in Contact Lenses? <u>O. Ucakhan-Gunduz</u> , Turkey	
11:12	Contact Lens Comfort/Discomfort Mechanisms <u>J. V. Aquavella</u> , USA	
11:24	Imaging of Tear Film During Contact Lens Wear <u>S. Koh</u> , Japan	
11:36	Drug-Eluting Contact Lens for the Treatments of Glaucoma and Ocular Inflammation <u>J. Ciolino</u> , USA	
11:48	Innervation in Ocular Surface Homeostasis <u>P. Aragona</u> , Italy	
12:00	Innervation of the Ocular Surface Dry Eye <u>J. Merayo Lloves</u> , Spain	
12:12	Management of the Patient with Corneal Neuralgia/Neuropathy <u>P. Hamrah</u> , USA	
12:24	Q&A	

Thursday, December 1, 2016

Morning Sessions – Hall C (Sala Carducci)

09:00-10:30	Neuro-Ophthalmology/Glaucoma Free Papers & Cases Chairs: L. Levin, USA & R. Huna-Baron, Israel	Hall C
09:00	Chromatic Multifocal Pupilperimetry for Objective Diagnosis of Neurodegeneration in the Eye and the Brain <u>L. Sher</u> , Israel	
09:10	Ab Interno Xen Gel Implantation for Treatment of Glaucoma Resistant to Previous Surgical Precedures – Case Series <u>J. Jablonska</u> , Poland	
09:20	Comparison of Safety and Efficacy between Hydrus and IStent Combined with Phacoemulsification in Open Angle Glaucoma Subjects: 24 Month Follow-Up <u>J. Jablonska</u> , Poland	
09:30	New Insights in Vanishing White Matter Disease - Unreported Manifestations, the Mildest Course and an Extensive Review <u>S. Barros</u> , Portugal	
09:40	Enigma of Bilateral Swollen Discs <u>R. Huna-Baron</u> , Israel	
09:50	Color Vision Assessment in Low Vision <u>C. Ripamonti</u> , UK	
10:00	Visual Outcome of Systemic Corticosteroids Treatment in Non-Arteritic Anterior Ischemic Optic Neuropathy <u>R. Huna-Baron</u> , Israel	
10:10	Q&A	
10:30-11:00	Coffee Break	
11:00-11:45	Inflammation Chair: <u>R. Neumann</u> , Israel	Hall C
11:00	Biologics: Drugs Which Can Induce Disorders Which They Also Can Cure <u>M. Zierhut</u> , Germany	
11:12	Systemic Vs Local Therapy <u>D. Goldstein</u> , USA	
11:24	Panel & Cases <u>E. Miserocchi</u> , Italy, <u>M. Kramer</u> , Israel, <u>D. Goldstein</u> , USA, <u>D. Chu</u> , USA, <u>M. Zierhut</u> , Germany	
11:45-12:30	Inflammation and Oncology Chair: <u>E. Miserocchi</u> , Italy	Hall C
11:45	Prognostic and Treatment Effect Modifying Baseline Factors for Visual Functioning Response in Non-Infectious Uveitis of the Posterior Segment Treated With Intravitreal Sirolimus <u>E. Miserocchi</u> , Italy	
11:55	Treating Uveitis with Subconjunctival Triamcinolone <u>A. L. Skarin</u> , Sweden	
12:05	Management of Postadenoviral Corneal Infiltrates. Clinical and Immunological Aspects <u>D. Maychuk</u> , Russia	
12:15	Solitary Fibrous Tumor of Lacrimal Sac – Case Report <u>B. Carvalho</u> , Portugal	
12:22	Combined Treatment for Advanced Retinoblastoma with Intraarterial and Intravireal Chemotherapy – Case Report <u>B. Carvalho</u> , Portugal	

Thursday, December 1, 2016

Afternoon Sessions – Hall A (Sala Loyola)

14:00-14:45	Panel Diabetic Macular Edema Chair: <u>P. Udaondo</u> , Spain	Hall A
14:00	Panel: Diabetic Macular Edema - Case Discussion <u>R. Singh</u> , USA, <u>P. Udaondo</u> , Spain, <u>B. D. Kuppermann</u> , USA, <u>A. Augustin</u> , Germany, <u>F. Boscia</u> , Italy	
14:45-15:30	Inhibition Diabetic Retinopathy Chair: <u>A. Das</u> , USA	Hall A
14:45	Targeting MMP-9 to Regulate the Development of Diabetic Retinopathy <u>R. Kowluru</u> , USA	
15:00	Targeting Vascular Inflammation in Early Stage Diabetic Retinopathy <u>J. Penn</u> , USA	
15:15	Nanomedicine Therapy in Diabetic Retinopathy <u>A. Ljubimov</u> , USA	
15:30-16:00	Coffee Break	
16:00-16:45	End Points Chair: <u>K. Csaky</u> , USA	Hall A
16:00	Determination of "Clinical Significance" in Neovascular Age Related Macular Degeneration Randomized Clinical Trials: Lessons from Previous Trials and Statistical Considerations <u>D. D'Amico</u> , USA	
16:20	Analysis of Secondary and Supportive Endpoints in Randomized Controlled Trials: Fundamental Underpinning and the Role of p-Value <u>K. Csaky</u> , USA	
16:40	Q&A	
16:45-17:45	End Points - Regulatory Perspective Chairs: <u>W. Chambers</u> , USA & <u>J. Moseley</u> , UK	Hall A
16:45	Historical Perspective of Endpoints in Ophthalmology <u>G. D. Novack</u> , USA	
17:00	Definition of Endpoints for Clinical Studies <u>W. Chambers</u> , USA	
17:15	Device Dependent Endpoints <u>M. Eydelman</u> , USA	
17:30	European Regulatory Perspective <u>J. Moseley</u> , UK	

Thursday, December 1, 2016

Afternoon Sessions – Hall B (Sala Foscolo)

14:00-14:45	Drug Development: Ethnic Variability Chair: F. Behar-Cohen, Switzerland	Hall B
14:00	Association between Snps of Metalloproteinases and Prostaglandin F2α Receptor Genes and Latanoprost Response in Open-Angle Glaucoma F. Ussa, UK	
14:15	Precision Medicine and Rare Genetic Variants M. Ingelman-Sundberg, Sweden	
14:30	How Omics Can Help Understand and Treat Eye Disease F. Behar-Cohen, Switzerland	
14:45-15:30	External Eye Diseases - Free Papers Chairs: V. Perez, USA & J. V. Aquavella, USA	Hall B
14:45	Principal Component Analysis of Tear Film Lipids and Related Ocular Surface Temperature J. V. Aquavella, USA	
14:55	The Use of Platelet-Rich Plasma for Chronic Cornea Erosions, Associated with Herpes Virus Keratitis A. Loshkareva, Russia	
15:05	Filamentary Keratitis Concomitant Diseases and Treatment Effectiveness I. Pronkin, Russia	
15:15	Safety and Efficacy Clinical Trials for SYL1001, a Novel siRNA for the Treatment of Dry Eye Disease A. M. Bleau, Spain	
15:25	Q&A	
15:30-16:00	Coffee Break	
16:00-16:45	End Points Chair: K. Csaky, USA	
	Main Presentations: Hall A For full program please refer to page 17	
16:45-17:45	End Points - Regulatory Perspective Chairs: W. Chambers, USA & J. Moseley, UK	
	Main Presentations: Hall A For full program please refer to page 17	

Thursday, December 1, 2016

Afternoon Sessions – Hall C (Sala Carducci)

14:00-14:45	Conclusions from Failing Clinical Trials Chair: <u>R. Neumann</u> , Israel & <u>M. De-Smet</u> , Germany	Hall C
14:00	Conclusions from Failing Clinical Trials <u>B. Bodhagi</u> , France	
14:15	Panel & Discussion <u>R. Neumann</u> , Israel, <u>B. Bodhagi</u> , France, <u>M. Kramer</u> , Israel, <u>D. Goldstein</u> , USA, <u>M. De-Smet</u> , Germany	
14:45-15:30	Inflammation - Cases Chair: <u>M. Kramer</u> , Israel	Hall C
14:45	Multimodal Imaging in a Case of Acute Macular Neuroretinopathy <u>M. Kramer</u> , Israel	
14:55	Brimonidine Eye Drops and Severe Acute Uveitis – Case Report <u>B. Carvalho</u> , Portugal	
15:05	Posterior Scleritis and Myelodysplasia in Relapsing Polychondritis - Therapeutic Challenge <u>S. Barros</u> , Portugal	
15:15	Ocular Hypotony in a Patient with Juvenile Idiopathic Arthritis Associated Uveitis- Therapeutic Challenge <u>E. Raskin</u> , Israel	
15:25	Q&A	
15:30-16:00	Coffee Break	
16:00-16:45	End Points Chair: <u>K. Csaky</u> , USA	
	Main Presentations: Hall A For full program please refer to page 17	
16:45-17:45	End Points - Regulatory Perspective Chairs: <u>W. Chambers</u> , USA & <u>J. Moseley</u> , UK	
	Main Presentations: Hall A For full program please refer to page 17	

Friday, December 2, 2016

Morning Sessions – Hall A (Sala Loyola)

09:00-10:30	Innovation in Ophthalmology Chair: R. Neumann, Israel	Hall A
09:00	Update on the Development of RVL 1201 for the Treatment of Blepharoptosis <u>B. Butler</u> , USA	
09:15	Non Aqueous, Preservative Free Ocular Drug Delivery Technology with Unique Properties <u>B. Günther</u> , Germany	
09:30	Results of a Randomized, Double-Masked, Placebo-Controlled Trial of Seciera (OTX-101), a Novel Nanomicellar Cyclosporine Ophthalmic Solution for Treatment of Keratoconjunctivitis Sicca <u>J. Tauber</u> , USA	
09:45	Introduction of PK-Eye™, a New Tool for Drug Development <u>B. Butler</u> , USA	
10:00	The Potential for Treatments for Posterior Eye Diseases Using a Suprachoroidal Injection Approach – What Has Been Learned <u>G. Noronha</u> , USA	
10:15	A New Signaling Pathway and Target for the Regulation of Intraocular Pressure Using an Adenosine Mimetic and the A1 Sub-Receptor <u>C. Rich</u> , USA	
10:30-11:00	Coffee Break	
11:00-12:30	Neuroprotection Chairs: L. Levin, USA & A. Viswanathan, UK	Hall A
11:00	Current Status of New Approaches to Neuroprotection in Optic Neuropathy <u>L. Levin</u> , USA	
11:15	Differential Effects of an Adenosine A1 Mimetic on Neuro-Enhancement and Neuro-Protection: Evidence from Nonclinical Models of Ocular Injury <u>C. Rich</u> , USA	
11:30	RPh201, a New Drug Candidate for Treatment of NAION <u>K. Adamsky</u> , Israel	
11:45	Bone Marrow Stem Cell Therapy for AION <u>N. Cohen-Goldberg</u> , Israel	
12:00	A Hemichannel Blocker Currently Undergoing Clinical Trials Reduces Inflammation and Prevents Retinal Damage in an Animal Model of Age Related Macular Degeneration <u>M. L. Acosta</u> , New Zealand	
12:15	Decreasing the Time Needed to Measure Visual Field Progression in Neuroprotection Trials <u>A. Viswanathan</u> , UK	
12:30-13:30	Alcon Sponsored Satellite Lunch Session: Brinzolamide/Brimonidine Fixed Combination in the Reduction of Intraocular Pressure in Open Angle Glaucoma	Hall A (Sala Loyola)

For full program please refer to page 39

Friday, December 2, 2016

Morning Sessions – Hall B (Sala Foscolo)

08:00-09:00	Infection - Free Papers Chair: E. Romanowski, USA	Hall B
08:00	Efficacy of Chloroquine-Doxycycline Combination Therapy on Co-Infection of Malaria and Onchocerciasis in Ahani-Achi, Enugu State of Nigeria <u>A. Akujobi</u> , Nigeria	
08:10	Is the Treatment of MRSA Endophthalmitis a Special Challenge? <u>R. P. Kowalski</u> , USA	
08:20	Insight Into The Corneal Wound Healing Response: Transcriptomic and Metabolomic Analysis of Corneal Epithelial Cells Challenged by Bacteria <u>K. Brothers</u> , USA	
08:30	The Choice between Phototherapeutic Keratectomy or Topical Medications in Cases of Acanthamoeba Keratitis <u>D. Maychuk</u> , Russia	
08:40	Evaluation of In-Vitro Dynamics of Acanthamoeba Corneal Strains Isolated from Contact Lens Wearers with Infectious Keratitis <u>W. Baltaza</u> , Poland	
08:50	Design and Development of Novel Antimicrobial Silver Metallodrug of Ciprofloxacin for the Treatment of Bacterial Keratitis <u>I. Milionis</u> , Greece	
09:00-10:30	Glaucoma Chair: B. Katz, USA	Hall B
09:00	Glaucoma Prevalence in Cataract Surgery: A Structured Analysis of the US Medicare Standard Analytic File <u>A. Shrivastava</u> , USA	
09:12	The Enemy of the Glaucomatologist is the Internist <u>J. Schultz</u> , USA	
09:24	Controversy and Consensus in the Treatment and Management of Children with Congenital Glaucoma <u>N. Medow</u> , USA	
09:36	Myopia: Epidemiology, Histology & its Relationship to Glaucoma <u>J. Jonas</u> , Germany	
09:48	Angle Closure Glaucoma and Choroid Thickness <u>Y. Dai</u> , China	
10:00	Maximal Medical Therapy – When is it reached? <u>A. Hommer</u> , Austria	
10:12	Q&A	
10:30-11:00	Coffee Break	

Friday, December 2, 2016

Morning Sessions – Hall B (Sala Foscolo)

11:00-12:30	Local Chemotherapy in Ocular Oncology Chair: <u>J. Pe'er</u> , Israel	Hall B
11:00	The Use of Mitomycin C in Treating Ocular Surface Tumors <u>S. Frenkel</u> , Israel	
11:10	Treating OSSN - Ocular Surface Squamous Neoplasia, by Topical 5FU <u>E. Midena</u> , Italy	
11:20	The Use of INF-Alpha2b in Treating OSSN (Ocular Surface Squamous Neoplasia) <u>A. Galor</u> , USA	
11:30	The Current Use of Various Drugs in Treating Ocular Surface Tumors and Comparison among the Drugs <u>J. Pe'er</u> , Israel	
11:40	Q&A for Topical Treatment Lectures	
11:50	Intravitreal Chemotherapy for Retinoblastoma <u>F. Munier</u> , Switzerland	
12:00	Intra-Arterial Chemotherapy for Retinoblastoma <u>L. Desjardins</u> , France	
12:10	Treating Vitreoretinal Lymphoma by Intravitreal Chemotherapy – 20 Years of Experience <u>J. Pe'er</u> , Israel	
12:20	Q&A for Lectures on Intraocular Treatments	
12:30-13:30	Alcon Sponsored Satellite Lunch Session: Brinzolamide/Brimonidine Fixed Combination in the Reduction of Intraocular Pressure in Open Angle Glaucoma	Hall A (Sala Loyola)

For full program please refer to page 39

Friday, December 2, 2016

Morning Sessions – Hall C (Sala Carducci)

08:00-09:00	Intraocular Steroids Chair: <u>F. Behar-Cohen</u> , Switzerland	Hall C
08:00	One Hormone, Two Actions: Anti and Pro-Inflammatory Effects of Glucocorticoids <u>P. Escher</u> , Switzerland	
08:12	Glucocorticoid Receptor and the Vessels <u>N. Farman</u> , France	
08:24	Ambiguous Role of Glucocorticoids on the Retina Neurons <u>A. Torriglia</u> , France	
08:36	Ozurdex / Illuvien/ TA - Clinical Use of Intraocular Steroids <u>I. Mantel</u> , Switzerland	
08:48	Newly MOA of Old Drugs Could Explain Clinical Response Profile of Different Steroids <u>F. Behar-Cohen</u> , Switzerland	
09:00-10:30	Central Serous Chorio-Retinopathy Chair: <u>F. Behar-Cohen</u> , Switzerland	
09:00	Pacchychoroid Spectrum <u>E. Bousquet</u> , France	
09:12	CSCR, CNV and AMD <u>E. Bousquet</u> , France	
09:24	Non-Damaging Laser Therapy of the Macula: Mechanisms and Application to CSCR <u>D. Lavinsky</u> , USA	
09:36	The Genetic of CSCR <u>E. de Jong</u> , Netherlands	
09:48	Hypothesis from CSCR Sub Retinal Fluid <u>F. Behar-Cohen</u> , Switzerland	
10:00	Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Non-Resolving Central Serous Chorioretinopathy with Diffuse Pigment Epitheliopathy <u>A. Daruich-Matet</u> , Switzerland	
10:12	Treatments for CSR <u>F. Behar-Cohen</u> , Switzerland	
10:24	Q&A	
10:30-11:00	Coffee Break	

Friday, December 2, 2016

Morning Sessions – Hall C (Sala Carducci)

11:00-12:30	Dry Eye Chairs: P. A. Asbell, USA & O. Ucakhan-Gunduz, Turkey	Hall C
11:00	Ocular Surface Mechanisms and MGD (Meibomian Gland Dysfunction) Go Together <u>J. V. Aquavella</u> , USA	
11:10	Lubricin: Translating an Idea into a Safe and Effective Treatment for Dry Eye Disease <u>D. Sullivan</u> , USA	
11:20	In Vivo Confocal Microscopy in Meibomian Gland Disorder <u>O. Ucakhan-Gunduz</u> , Turkey	
11:30	Oxidative Stress in Dry Eye Pathogenesis <u>P. Aragona</u> , Italy	
11:40	Dry Eye and Glaucoma - The Impact on Patient's Compliance <u>I. P. Singh</u> , USA	
11:50	Organ Specific Disaccharides in the Ocular Surface <u>J. Merayo Lloves</u> , Spain	
12:00	What is the Best Refractive Treatment for a Patient with Ocular Surface Disease (LASIK, Epilasik, Anterior Chamber Implant, Cornea Implant, Femtosecond Arcuates) <u>R. Toyos</u> , USA	
12:10	Digital Devices and Dry Eye <u>M. M. Hom</u> , USA	
12:20	The Role of Autoimmune Disease in Ocular Surface Disease <u>I. P. Singh</u> , USA	
12:30-13:30	Alcon Sponsored Satellite Lunch Session: Brinzolamide/Brimonidine Fixed Combination in the Reduction of Intraocular Pressure in Open Angle Glaucoma	Hall A (Sala Loyola)

For full program please refer to page 39

Friday, December 2, 2016

Afternoon Sessions – Hall A (Sala Logola)

14:00-15:30	Dry AMD Chair: <u>J. M. Seddon</u> , USA	Hall A
14:00	Dry AMD: How Pathophysiology Provides a Wealth of Treatment Opportunities <u>T. Aslam</u> , UK	
14:10	Genotypes-Phenotypes and Risk Factors for AMD <u>J. M. Seddon</u> , USA	
14:20	Choroidal Round Hyporeflectivities in Geographic Atrophy <u>F. Bandello</u> , Italy	
14:30	Photoreceptor Imaging and Optical Coherence Tomography Angiography in Age-Related Macular Degeneration with Geographic Atrophy <u>J. L. Duncan</u> , USA	
14:40	Early Middle-Age Cholesterol Levels and the Risk of Age-Related Maculopathy <u>I. Immonen</u> , Finland	
14:50	Role of Anti VEGF and Lampalizumab in the Progression and Treatment of Geography Atrophy <u>A. Garcia-Layana</u> , Spain	
15:00	Targeting Macrophages in Age-Related Macular Degeneration with a Dendrimeric Therapy <u>G. A. Luty</u> , USA	
15:10	Scotopic Microperimetry in Dry Age-Related Macular Degeneration (AMD) <u>K. Csaky</u> , USA	
15:20	Q&A	
15:30-16:00	Coffee Break	
16:00-17:30	Imaging Chair: <u>G. Soubrane-Daguet</u> , France	Hall A
16:00	First Step: Correct Diagnosis <u>J. J. De Laey</u> , Belgium	
16:10	Retinal Pigment Epithelium <u>K. Gocho</u> , Japan	
16:20	Photoreceptor <u>M. Saleh</u> , France	
16:30	Muller Cells (+ILM) <u>M. Rehak</u> , Germany	
16:40	Choroidal Imaging <u>J. Uzzan</u> , France	
16:50	Quantification of Retinal Microvascular Density in Cirrus Angioplex Oct Angiography (OCTA) Images in Diabetic Retinopathy <u>J. Cunha-Vaz</u> , Portugal	
17:00	Retinal Vessels <u>F. Behar-Cohen</u> , Switzerland	
17:10	Morphology and Evolution of CNV Recurrences <u>B. Lumbroso</u> , Italy	
17:20	Agreement between Oct-Leakage and Fluorescein Angiography to Identify Sites of Alteration of The Blood-Retinal Barrier in Diabetes <u>J. Cunha-Vaz</u> , Portugal	

Friday, December 2, 2016

Afternoon Sessions – Hall B (Sala Foscolo)

14:00-15:30	Drug Delivery Chairs: <u>D. Tang-Liu</u> , USA & <u>R. Gurny</u> , Switzerland	Hall B
14:00	Pharmaceutical Development Activities Pertaining to Ocular Long Acting Delivery <u>G. Schwach</u> , Switzerland	
14:15	Recent Advances in Electroporation <u>F. Behar-Cohen</u> , Switzerland	
14:30	Engineering Antibody Fabs for Long Acting Delivery to the Eye <u>B. Kelley</u> , USA	
14:45	Antifungal Treatment: What Drug Delivery Strategy? <u>D. Gabriel</u> , Switzerland	
15:00	PP-001 a Novel Anti-Inflammatory Drug for Intravitreal Treatment of Posterior Uveitis <u>F. Obermayr</u> , Germany	
15:15	ENV515 Travoprost XR for Glaucoma: Clinical Development Update <u>B. R. Yerxa</u> , USA	
15:30-16:00	Coffee Break	
16:00-17:30	Drug Delivery Chairs: <u>D. Tang-Liu</u> , USA & <u>R. Gurny</u> , Switzerland	Hall B
16:00	Bimatoprost Sustained-Release Implants: A Novel Drug Delivery Approach to Meet Unmet Patient Needs <u>S. Neervannan</u> , USA	
16:15	Using Ex Vivo/In Vivo Animal Models to Investigate Local Drug Delivery to the Human Eye <u>Y. Kalia</u> , Switzerland	
16:30	Understanding and Overcoming the Challenges of Ocular Tolerability of Long-Acting Delivery Systems for Delivering Macromolecules to the Back of the Eye <u>A. Daugherty</u> , USA	
16:45	Topical Delivery of Lipophilic Drugs to the Anterior and Posterior Segments of Eyes <u>D. Wassel</u> , USA	
17:00	Panel Discussion <u>D. Tang-Liu</u> , USA & <u>R. Gurny</u> , Switzerland	

Friday, December 2, 2016

Afternoon Sessions – Hall C (Sala Carducci)

14:00-14:45	Ocular Allergy Chair: <u>E. Akpek</u> , USA	Hall C
14:00	Introduction to Allergic Conjunctivitis <u>E. Akpek</u> , USA	
14:15	Immunomodulatory Treatment of Allergic Keratoconjunctivitis <u>S. Doan</u> , France	
14:30	Childhood Vernal Keratoconjunctivitis and Keratoconus <u>W. May</u> , USA	
14:45-15:30	Cases Allergy Chair: <u>E. Akpek</u> , USA	Hall C
15:30-16:00	Coffee Break	
16:00-17:30	Uveitis – Hot Topics Chair: <u>E. Miserocchi</u> , Italy	Hall C
16:00	Changing Patterns of Uveitis Epidemiology in Europe <u>E. Miserocchi</u> , Italy	
16:12	Imaging in the World of Inflammation <u>M. Kramer</u> , Israel	
16:24	Ramifications of Uveitis Management: "Glaucoma and Uveitis" <u>D. Chu</u> , USA	
16:36	Tuberculosis - Regaining a Lead Position in Present Uveitis Entities - Therapeutic Implications <u>J. Merayo Lloves</u> , Spain	
16:48	New Face of Tuberculosis Uveitis as Reflected Globally - Clinical Presentation and Therapy <u>R. Agarwal</u> , India	
17:00	The Economic Impact of Biological Treatment in Behcet Uveitis <u>M. Accorinti</u> , Italy	
17:12	The Curse and Blessing of Steroids in Infectious Ocular Diseases <u>Y. El-Shabrawi</u> , Austria	
17:24	Q&A	

Saturday, December 3, 2016

Morning Sessions – Hall A (Sala Loyola)

09:00-10:30	Investigator Initiated Multicenter Trials Chair: <u>J. Cunha-Vaz</u> , Portugal	Hall A
09:00	European Experience <u>J. Cunha-Vaz</u> , Portugal	
09:14	Ophthalmic Endpoints in Pivotal Drug Development Trials; Scientific Advice at the EMA <u>J. Moseley</u> , UK	
09:28	Health Economics Perspective <u>F. Batel-Marques</u> , Portugal	
09:42	Investigator Initiated Multinational Studies: Challenges <u>C. Martinho</u> , Portugal	
09:56	Industry Perspective <u>G. Lambrou</u> , Switzerland	
10:10	Q&A	
10:30-11:00	Coffee Break	
11:00-11:45	End Points II Chair: <u>F. Drago</u> , Italy	Hall A
11:00	The New GCP Rules: Application in Ophthalmology <u>S. Petraglia</u> , Italy	
11:15	Imaging Tools for Clinical Research in Ophthalmology <u>G. Garhofer</u> , Austria	
11:30	Clinical Studies in Ophthalmology: Twenty Years of Progress <u>J. Cunha-Vaz</u> , Portugal	
11:45-12:30	EVER – The Need for Objective and Quantitative Measurement Methods for Clinical Practice and Clinical Trials in (Posterior) Uveitis Chairs: <u>P. Neri</u> , Italy & <u>C. P. Herbort Jr.</u> , Switzerland	Hall A
11:45	Quantitative Laser Flare Photometry to Replace Qualitative Measurement of Global Intraocular Inflammation <u>C. P. Herbort Jr.</u> , Switzerland	
12:00	Quantitative Measurement of Inflammation in Posterior Segment Uveitis Using a Dual FA/ICGA Angiographic Scoring System <u>C. P. Herbort Jr.</u> , Switzerland	
12:15	Objective Measurement of Posterior Pole Inflammation in Uveitis Using OCT <u>P. Neri</u> , Italy	

Saturday, December 3, 2016

Morning Sessions – Hall B (Sala Foscolo)

08:00-09:00	Retina - Free Papers II Chair: <u>F. Bandello</u> , Italy	Hall B
08:00	Real World Outcomes and Prognostic Factors at 1 Year with Bevacizumab in Diabetic Macular Edema in Portuguese Patients with Low Baseline Visual Acuity <u>S. Barros</u> , Portugal	
08:10	Characterisation of a Crossmab Antibody Targeting VEGF-A and Ang2 for Neovascular Diseases of the Eye <u>G. Hartmann</u> , Germany	
08:20	Anatomical and Functional Results After Ranibizumab Treatment for Short-Duration Diabetic Macular Edema in Current Clinical Practice <u>F. A. Manco Lavado</u> , Spain	
08:30	Efficacy of a 0.2micrograms/Day Fluocinolone Acetonide Implant (ILUVIEN) in Eyes with Chronic Diabetic Macular Edema and Prior Vitrectomy <u>A. Augustin</u> , Germany	
08:40	Q&A	
09:00-09:45	Neuro-Ophthalmology Chair: <u>B. Katz</u> , USA	Hall B
09:00	NAION – Is It Really Ischemic? <u>C. Parsa</u> , Bulgaria	
09:10	Vitreopapillary Traction : Signs and Symptoms <u>B. Katz</u> , USA	
09:20	Therapies for Giant Cell Arteritis <u>K. Landau</u> , Switzerland	
09:30	Nonarteritic Anterior Ischaemic Optic Neuropathy - Therapeutic Interventions <u>S. Tow</u> , Singapore	
09:40	Q&A	
09:45-10:30	Miscellaneous Retinal Disorders Chair: <u>D. Saperstein</u> , USA	Hall B
09:45	Orally-Delivered, Synthetic Chromophore Therapy for Inherited Retinal Disease due to Genetic Defects in the Visual Cycle <u>D. Saperstein</u> , USA	
09:57	Overview of Stem Cell Trials in the Retina <u>H. Klassen</u> , USA	
10:09	Tissue Plasminogen Activator Assisted Displacement of Subretinal Hemorrhage Modified with Inferior Limited Retinal Detachment <u>D. Saperstein</u> , USA	
10:21	Q&A	
10:30-11:00	Coffee Break	

Saturday, December 3, 2016

Morning Sessions – Hall B (Sala Foscolo)

11:00-12:30	Ocular Infections Chair: <u>I. Barequet</u> , Israel	Hall B
11:00	Different Practice Patterns in Endophthalmitis Prophylaxis in Different Parts of the World <u>A. Grzybowski</u> , Poland	
11:10	Antibiotics in Endophthalmitis - Facts and Beliefs <u>A. Grzybowski</u> , Poland	
11:20	Early Penetrating Keratoplasty a Chaud in Therapy-Resistant Acanthamoeba Keratitis <u>B. Seitz</u> , Germany	
11:30	Amplivue®: the Validation of a New Practical and Timely Diagnostic Test for Detecting HSV from Ocular Specimens <u>R. P. Kowalski</u> , USA	
11:40	Endophthalmitis Prophylaxis Using a Single Thermos-Responsive Gel-Drop Containing Controlled-Release Moxifloxacin Loaded Microspheres in Rabbit Model <u>E. Romanowski</u> , USA	
11:50	Microbiological Profile of Diabetic Patients Undergoing Anti-VEGF Intravitreal Injections <u>I. Barequet</u> , Israel	
12:00	Ocular Host-Pathogen Interactions <u>R. M. Shanks</u> , USA	
12:10	The Arrhenius Equation and the Worldwide Renu-Related Fusarium Keratitis Event of 2004-2006 <u>J. D. Bullock</u> , USA	
12:20	Q&A	

Saturday, December 3, 2016

Morning Sessions – Hall C (Sala Carducci)

08:30-09:30	External Eye Diseases - Cases Chair: <u>J. Tauber</u> , USA	Hall C
08:30	Infliximab as an Adjunct Surgical Therapy of Ectodermal Dysplasia <u>J. V. Aquavella</u> , USA	
08:42	Rosacea Blepharconjunctivitis Treated with a Novel Preparation of Dilute Povidone Iodine and Dimethylsulfoxide: a Case Report and Review of the Literature <u>J. Pelletier</u> , USA	
08:54	Diagnostic Issues of Thygeson's Keratitis and Treatment Options <u>D. Maychuk</u> , Russia	
09:06	Burning Mouth, Burning Eyes: a Case Study <u>S. Hauswirth</u> , USA	
09:30-10:30	Improved Outcomes of Corneal Infections Chair: <u>P. A. Asbell</u> , USA	Hall C
09:30	How to Prevent and Treat Inflammation and Infection in Cataract Surgery - Modern Pre Treatment Strategies, Drops, Biologics, Implants and More <u>R. Toyos</u> , USA	
09:45	Degeneration and Regeneration of Corneal Nerves after Infectious Keratitis <u>P. Hamrah</u> , USA	
10:00	TRUST/ARMOR--Role of Surveillance Studies <u>P. A. Asbell</u> , USA	
10:15	Q&A	
10:30-11:00	Coffee Break	
11:00-12:30	Retinal Vein Occlusion Chair: <u>F. Boscia</u> , Italy	Hall C
11:00	BRIGHTER and CRYSTAL Studies <u>F. Boscia</u> , Italy	
11:15	VIBRANT Trial <u>P. Udaondo</u> , Spain	
11:30	Steroids for RVO <u>A. Augustin</u> , Germany	
11:45	Laser for RVO (Mechanism) <u>F. Bandello</u> , Italy	
12:00	Panel: RVO - Case Discussion <u>F. Boscia</u> , Italy, <u>A. Augustin</u> , Germany, <u>P. Udaondo</u> , Spain, <u>F. Bandello</u> , Italy	

Saturday, December 3, 2016

Afternoon Sessions – Hall A (Sala Loyola)

14:00-15:30	Dry Eye Chairs: <u>P. A. Asbell</u> , USA & <u>R. Dana</u> , USA	Hall A
14:00	Novel Treatments for Dry Eye <u>R. Herrero-Vanrell</u> , Spain	
14:10	Steroids in Dry Eye <u>P. Aragona</u> , Italy	
14:20	Plasma Rich Growth Factors in Ocular Surface Disease <u>J. Merayo Lloves</u> , Spain	
14:30	New Dry Eye Treatments Based on Tear Film Oriented Therapy <u>S. Koh</u> , Japan	
14:40	Pharmacology for Dry Eye - Is There Anything New Under the Sun? <u>G. D. Novack</u> , USA	
14:50	Graft-Versus-Host Disease (GVHD) - an Area of Significant Unmet Medical Need in Ocular Surface Disease <u>R. Dana</u> , USA	
15:00	Update in Immune Mechanisms of Ocular GVHD <u>V. Perez</u> , USA	
15:10	Baseline Characteristics of Participants in the Dry Eye Assessment and Management (Dream) Study <u>P. A. Asbell</u> , USA	
15:20	Q&A	
15:30-16:00	Coffee Break	
16:00-16:45	Wound Healing Chairs: <u>P. A. Asbell</u> , USA & <u>Victor L. Perez</u> , USA	Hall A
16:00	Effect of Amniotic Membrane Suspension (AMS) and Amniotic Membrane Homogenate (AMH) on Human Corneal Epithelial Cell (HCEC) Viability, Migration and Proliferation In-Vitro <u>B. Seitz</u> , Germany	
16:10	Use of Blood Products in the Treatment of Ocular Surface Diseases <u>V. Perez</u> , USA	
16:20	Effect of Human Autologous Serum and Fetal Bovine Serum on Human Corneal Epithelial Cell Viability, Migration and Proliferation In-Vitro <u>B. Seitz</u> , Germany	
16:30	Corneal Endothelial Tissue Engineering <u>J. Merayo Lloves</u> , Spain	
16:40	Q&A	
16:45-17:30	Corneal Surgery Chairs: <u>P. A. Asbell</u> , USA & <u>O. Ucakhan-Gunduz</u> , Turkey	Hall A
16:45	DALK <u>V. Sarnicola</u> , Italy	
17:00	New Immune Modulation Strategies in Corneal Transplantation <u>R. Dana</u> , USA	
17:15	Pediatric Versus Adult Corneal Cross-Linking <u>O. Ucakhan-Gunduz</u> , Turkey	

Saturday, December 3, 2016

Morning Sessions – Hall B (Sala Foscolo)

14:00-15:30	Therapy for Retinal Vascular Diseases Chair: <u>A. Das</u> , USA	Hall B
14:00	Kallikrein-Kinin System in Diabetic Retinopathy <u>E. Feener</u> , USA	
14:15	Hypoxia Inducible Factor and Diabetic Eye Disease: All Roads Do Not Lead to VEGF <u>A. Sodhi</u> , USA	
14:30	Inflammaging and Diabetic Retinopathy <u>M. Bartoli</u> , USA	
14:45	Hypoxia Targeted Therapies in Retinal Diseases <u>A. Jayagopal</u> , Switzerland	
15:00	iPSCs: an Emerging Therapy for Diabetic Retinopathy and Macular Ischemia <u>M. Grant</u> , USA	
15:15	Q&A	
15:30-16:00	Coffee Break	
16:00-17:30	Ocular Drug Development: Stability vs. Change Chair: <u>J. Cagle</u> , USA	Hall B
16:00	"Innovation has Left the Building" - Has Innovation Migrated to Small/Medium Companies? <u>B. Butler</u> , USA	
16:12	How Can Small Companies Deal with Regulatory Demands Designed to be Met by Big Pharma? Smaller Companies' Consortium: Dream or Reality <u>J. Cagle</u> , USA	
16:24	Social Policy: is it Right to be Liberal in Lowering the Regulatory Bars for Clinical Trials of Novel Investigational Ophthalmic Therapies? Preclinical Requirements <u>G. D. Novack</u> , USA	
16:36	Biomimicry - Medical Innovations Inspired by Nature <u>D. H. Langford</u> , Israel	
16:48	How Clinical Development has been Coping in the Last 10 Years <u>O. Cuzzani</u> , USA	
17:00	What Determines What Patients for Pay Medications? <u>G. D. Novack</u> , USA	
17:12	Q&A	

Saturday, December 3, 2016

Morning Sessions – Hall C (Sala Carducci)

14:00-15:30	Glaucoma Chair: <u>B. Katz</u> , USA	Hall C
14:00	Rhokinae Inhibitors <u>L. J. Katz</u> , USA	
14:12	Future of Stem Cell Therapy in Glaucoma <u>P. Kaufman</u> , USA	
14:24	Genetic Therapies for Glaucoma <u>P. Kaufman</u> , USA	
14:36	Treating Glaucoma with Drugs: Anything Better than Eyedrops? <u>S. Gandolfi</u> , Italy	
14:48	Long-Term Safety and Efficacy of a Novel Bimatoprost Ocular Insert: Results of a 1-Year Open-Label Extension Study <u>J. D. Brandt</u> , USA	
15:00	Q&A	
15:30-16:00	Coffee Break	
16:00-17:30	Retina – Free Papers III Chairs: <u>P. Lanzetta</u> , Italy & <u>F. Boscia</u> , Italy	Hall C
16:00	A Subretinal Fibrosis Disease Model in Mice Developed from Laser Induced CNV <u>M. Ju</u> , USA	
16:10	Effect of Laser Physical Parameters on Lesion Size in Retinal Photocoagulating Surgery: Clinical OCT and Experimental Study <u>A. Soleimani</u> , Iran	
16:20	Efficacy of Systemic Diclofenac Sodium on Intravitreal Concentration in Rabbits <u>M. Abrishami</u> , Iran	
16:30	Rod-Derived Cone Viability Factor Delivery Through Adeno-Associated Viral Vector, the Pass Toward the Clinic for Treating Retinitis Pigmentosa <u>E. Clérin</u> , France	
16:40	Intravitreal Administration of Adenosine A2A Receptor Antagonist Controls Microglia-Mediated Neuroinflammation in a Diabetic Retinopathy Mouse Model <u>A. R. Santiago</u> , Portugal	
16:50	Treatment with an A2A Receptor Antagonist Reduces Neuroinflammation and Protects the Retina Against Ischemic Damage <u>F. Ambrosio</u> , Portugal	
17:00	Amelioration of Amyloid β Induced retinal Inflammatory Responses by a LXR Agonist TO901317 is Associated with Inhibiting of the NF-κB signaling and NLRP3 <u>B. Lei</u> , China	
17:10	Bone Morphogenetic Protein-2 Signal Pathway in Diabetic Retinopathy <u>M. Al-Shabraway</u> , USA	
17:20	Acute Cystoid Macular Edema in Reduced General State of Health Because of Event of Death in Family - a Case Series of 3 Eyes <u>A. Borkenstein</u> , Austria	



The International Symposium on
Ocular Pharmacology & Therapeutics

13th ISOPT *Clinical*

Industry Sponsored Program



www.ISOPTClinical.com

Brinzolamide/brimonidine fixed combination in the reduction of intraocular pressure in open-angle glaucoma

an Alcon-sponsored satellite symposium

AGENDA: 2 DECEMBER 2016


Hall A, Sala Loyola, Roma Eventi Fontana di Trevi

Time	Topic
12:45	Chairman's introduction – Prof. Stefano Gandolfi (Italy)
12:50	Quality of life in glaucoma patients – Mr Ananth Viswanathan (UK)
13:00	Pivotal studies on brinzolamide/brimonidine fixed combination – Prof. Stefano Gandolfi (Italy)
13:15	Real-life experience with brinzolamidine/brimonidine fixed combination in patients with open-angle glaucoma – Prof. Ines Lanzl (Germany)
13:25	Audience questions
13:30	End and refreshments

Friday, December 2, 2016

Morning Sessions – Hall A (Sala Loyola)

12:30-13:30	Alcon Sponsored Satellite Lunch Session: Brinzolamide/Brimonidine Fixed Combination in the Reduction of Intraocular Pressure in Open Angle Glaucoma Chair: <u>S. Gandolfi</u> , Italy	Hall A (Sala Loyola)
12:30	Meeting Room Set-Up from Previous Session	
12:45	Chairman's Introduction <u>S. Gandolfi</u> , Italy	
12:50	Quality of Life in Glaucoma Patients <u>A. Viswanathan</u> , UK	
13:00	Pivotal Studies on Brinzolamide/Brimonidine Fixed Combination <u>S. Gandolfi</u> , Italy	
13:15	Real-Life Experience with Brinzolamidine/Brimonidine Fixed Combination in Patients with Open-Angle Glaucoma <u>I. Lanzl</u> , Germany	
13:25	Audience Questions	
13:30	End and refreshments	





ISOPT Clinical
Rome Italy, December 2016



WINDMAN
IMAGINE THAT

Symposium Organizers:

Windman Events Ltd.

15 A Brazil Street, Tel Aviv, Israel 6946025

Email: info@windman.co.il, Website: www.windman.co.il

Email: office@isoptclinical.com, Website: www.isoptclinical.com